International Stem Cell CORP

International Stem Cell Corporation has finalized the sale of its subsidiary, Lifeline Cell Technology, LLC, to American Type Culture Collection, Inc. for $25.25 million.

International Stem Cell Corporation stockholders elected four directors at the 2026 Annual Meeting held on June 11, 2026.

International Stem Cell Corporation held its Annual Meeting, electing four directors and approving executive compensation on an advisory basis.

International Stem Cell Corporation has extended the maturity date of a $2.5 million loan from its Co-Chairman and CEO, Dr. Andrey Semechkin, until September 15, 2026, highlighting ongoing financial reliance.

International Stem Cell Corporation has extended the maturity date of a $2.9 million loan by issuing a new $2.7 million promissory note to Dr. Andrey Semechkin, with a maturity date of September 15, 2025.

International Stem Cell Corporation reported a net income of $57,000 for Q3 2025, a significant improvement from the prior year's loss, but continues to raise substantial doubt about its ability to continue as a going concern.

International Stem Cell Corporation reported a wider net loss of $127,000 for the first six months of 2025, alongside a going concern warning, despite increased product sales and significant R&D investment.

International Stem Cell Corporation's Q1 2025 results show stable revenue with ongoing efforts to secure additional funding for research and development.

International Stem Cell Corporation's Q3 2024 results show increased product sales but continued net losses and concerns about the company's ability to continue as a going concern.

International Stem Cell Corporation's Q2 2024 results show a revenue increase driven by biomedical sales, but the company still reports a net loss and faces going concern challenges.

International Stem Cell Corporation's first quarter 2024 results show a slight increase in product sales but a larger net loss compared to the same period last year.

International Stem Cell Corporation's 10-K filing reveals a 17% increase in product sales driven by biomedical market growth, alongside ongoing efforts in therapeutic development and a going concern uncertainty.

International Stem Cell Corporation's annual 10-K filing reveals continued operating losses and a reliance on commercial businesses to fund research and development, while highlighting progress in clinical trials for Parkinson's disease.

Paul Maier V, a Director of International Stem Cell CORP, reported a transaction in 30,000 shares of common stock on September 16, 2026.

Paul Maier V, a Director of International Stem Cell CORP, sold 32,802 shares of common stock on September 11, 2026 for $0.32 per share.

International Stem Cell Corp's Director Don Wright was granted 562,786 stock options with an exercise price of $0.13, vesting through June 2026 and expiring in June 2035.

Paul V. Maier, a Director at International Stem Cell Corp., was granted stock options for a total of 562,786 shares of common stock with an exercise price of $0.13 per share.

Director Don Wright acquired stock options in International Stem Cell CORP on June 11, 2024.

Paul V. Maier, a director at International Stem Cell CORP, reports the acquisition of stock options.

International Stem Cell Corporation announces its annual meeting of stockholders to be held virtually on June 17, 2025, covering director elections, executive compensation, and say-on-pay frequency.

International Stem Cell Corporation will hold its annual meeting of stockholders virtually on June 11, 2024, to elect directors and transact other business.